Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma

<b><i>Background:</i></b> Differentiated thyroid carcinoma (DTC) in pediatric patients has specific clinical, pathological, and molecular characteristics, making its management different from that of adults. Our study aimed to evaluate the outcome and factors associated with persistent disease in a large cohort of pediatric patients. <b><i>Methods:</i></b> We performed a multicenter retrospective cohort study, including patients aged ≤18 years, diagnosed with a DTC, since January 2000. Both biochemical (BIR) and structural (SIR) incomplete responses were evaluated. <b><i>Results:</i></b> We included 538 patients, 401/538 (74.5%) females, with a median age of 15 years (interquartile range [IQR] 13-17 years). Papillary thyroid cancer was the most prevalent histotype and 277/530 (52.3%) had lymph node metastases at diagnosis. Vascular invasion and gross extrathyroidal extension (ETE) were reported in 133/326 (40.8%) and 91/533 (17.1%) of patients, respectively. T4 tumors represented 5% of the entire cohort. Radioactive iodine treatment (RAIT) was administered to 493/533 (92.5%) patients, and among them 138/493 (28%) received more than one RAIT cycle. After a median follow-up of 85 months (IQR 42-126 months), 414/538 patients (77%) had no evidence of disease and 124/538 patients (23.0%) a disease persistence: BIR in 68/538 patients (12.6%) and SIR in 56/538 patients (10.4%). In a multivariable analysis, the features significantly associated with persistent disease (BIR or SIR) were gross ETE (odds ratio [OR] 2.81, confidence interval [CI] 1.49-5.32, <i>p</i> = 0.0015) and lymph node uptake at whole-body scan (WBS) after the first RAIT (OR 3.31, CI 1.77-6.19, <i>p</i> = 0.0002). Multivariable analysis showed that the features significantly associated with SIR were T4 tumor (OR 4.3, CI 1.38-13.44, <i>p</i> = 0.01) and lymph node uptake at WBS after the first RAIT (OR 3.39, CI 1.5-7.67, <i>p</i> = 0.003). <b><i>Conclusions:</i></b> Our study of a very large series of pediatric DTC with long follow-up provides valuable insights into the clinical and pathological features associated with disease persistence. We identified T4 tumor, lymph node uptake on WBS, and gross ETE as independent factors associated with persistent disease. These findings emphasize the importance of careful risk stratification in pediatric DTC, allowing for more individualized treatment approaches.

Authors

Institutions

Publication Details

Journal
Thyroid
Published
2025-09-01
DOI
https://doi.org/10.1177/10507256251363978
Citations
1
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.29
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma

Gabriella Pellegriti, Emanuela Arvat, Małgorzata Waśniewska, Rita Ortolano et al.
1 citations
Thyroid
Thyroid Cancer Diagnosis and Treatment
1.29
article

Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma

Gabriella Pellegriti, Emanuela Arvat, Małgorzata Waśniewska, Rita Ortolano, Barbara Puligheddu, Maria Grazia Castagna, Giulia Brigante, Simone De Leo, Marcello Giachetti, Marco Russo, Carlotta Pozza, Caterina Mian, Rossella Elisei, Gerdi Tuli, Gerardo Esposito, Manlio Cabria, Maria Cristina Vigone, Maria Chiara Zatelli, Laura Fugazzola, Federica Alessandra Vianello, Valeria Bottici, Francesco Giorgino, Maria Laura Tanda, Francesco Felicetti, Alessia Dolci, Vincenzo Rochira
article en
1 citations

Abstract

<b><i>Background:</i></b> Differentiated thyroid carcinoma (DTC) in pediatric patients has specific clinical, pathological, and molecular characteristics, making its management different from that of adults. Our study aimed to evaluate the outcome and factors associated with persistent disease in a large cohort of pediatric patients. <b><i>Methods:</i></b> We performed a multicenter retrospective cohort study, including patients aged ≤18 years, diagnosed with a DTC, since January 2000. Both biochemical (BIR) and structural (SIR) incomplete responses were evaluated. <b><i>Results:</i></b> We included 538 patients, 401/538 (74.5%) females, with a median age of 15 years (interquartile range [IQR] 13-17 years). Papillary thyroid cancer was the most prevalent histotype and 277/530 (52.3%) had lymph node metastases at diagnosis. Vascular invasion and gross extrathyroidal extension (ETE) were reported in 133/326 (40.8%) and 91/533 (17.1%) of patients, respectively. T4 tumors represented 5% of the entire cohort. Radioactive iodine treatment (RAIT) was administered to 493/533 (92.5%) patients, and among them 138/493 (28%) received more than one RAIT cycle. After a median follow-up of 85 months (IQR 42-126 months), 414/538 patients (77%) had no evidence of disease and 124/538 patients (23.0%) a disease persistence: BIR in 68/538 patients (12.6%) and SIR in 56/538 patients (10.4%). In a multivariable analysis, the features significantly associated with persistent disease (BIR or SIR) were gross ETE (odds ratio [OR] 2.81, confidence interval [CI] 1.49-5.32, <i>p</i> = 0.0015) and lymph node uptake at whole-body scan (WBS) after the first RAIT (OR 3.31, CI 1.77-6.19, <i>p</i> = 0.0002). Multivariable analysis showed that the features significantly associated with SIR were T4 tumor (OR 4.3, CI 1.38-13.44, <i>p</i> = 0.01) and lymph node uptake at WBS after the first RAIT (OR 3.39, CI 1.5-7.67, <i>p</i> = 0.003). <b><i>Conclusions:</i></b> Our study of a very large series of pediatric DTC with long follow-up provides valuable insights into the clinical and pathological features associated with disease persistence. We identified T4 tumor, lymph node uptake on WBS, and gross ETE as independent factors associated with persistent disease. These findings emphasize the importance of careful risk stratification in pediatric DTC, allowing for more individualized treatment approaches.

ThyroidVol. 35(9)
University of Siena (IT), University of Messina (IT), University of Insubria (IT), University of Modena and Reggio Emilia (IT), University of Padua (IT), Vita-Salute San Raffaele University (IT), University of Milan (IT), University of Ferrara (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Ente Ospedaliero Ospedali Galliera (IT), University of Catania (IT), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Ospedale Garibaldi (IT), Azienda Ospedaliero-Universitaria di Modena (IT), Istituto Oncologico Veneto (IT), Ospedale Humanitas Gradenigo (IT), Azienda USL di Bologna (IT), Azienda Ospedaliera S.Maria (IT), IRCCS Istituto Auxologico Italiano (IT), Ospedale Regina Margherita (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Ospedale Valduce (IT), Azienda Ospedaliera Universitaria Pisana (IT), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), University of Turin (IT), University of Bari Aldo Moro (IT), Sapienza University of Rome (IT)
Openalex Percentile: Top 17%
Thyroid Cancer Diagnosis and Treatment
1.29
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.